HIGHLIGHTS
- who: Matthijs D. Kruizinga from the Centre for Human Drug Research CL Leiden, the Netherlands Department of Clinical Genetics, Leiden University Medical Centre have published the paper: Finding Suitable Clinical Endpoints for a Potential Treatment of a Rare Genetic Disease: the Case of ARID1B, in the Journal: (JOURNAL)
- what: The aim of this study is to explore a novel approach towards developing new endpoints for neurodevelopmental disorders in this case for ARID1B-related ID.
- future: While the included tests have at least a theoretical relationship between disease severity and test outcome as outlined . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.